Sara Tolaney: Interesting data from Mafalda Oliveira from SERENA-2 at ESMO Breast24

Sara Tolaney shared a post on X:

”Interesting data from Mafalda Oliveira from SERENA-2 demonstrating a greater reduction in ESR1m with camizestrant vs fulvestrant at C2D1 and at time or progression; early reduction in ESR1m predicts improved PFS with camizestrant.”

Source: Sara Tolaney/X

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications in leading scientific journals. She is the recipient of the Lee M Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty.